Home
HelpTest ID RASFP RAS/RAF Targeted Gene Panel by Next-Generation Sequencing, Tumor
Advisory Information
At least 20% tumor is required for this assay. The amount of tissue needed is dependent on a variety of preanalytical factors (eg, cellularity, ischemic time, fixation). In general, the minimum specimen adequacy for this test is approximately a 6 mm(2) area of tissue (can be over multiple slides from one tissue block) or 5,000 total cells (5,000 total nucleated cells if using cytology slides).
Necessary Information
A pathology report must accompany specimen in order for testing to be performed.
Specimen Required
Preferred:
Specimen Type: Tissue
Container/Tube: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block.
Acceptable:
Specimen Type: Tissue
Slides: 1 stained and 10 unstained
Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 10 unstained, unbaked slides with 5-micron thick sections of the tumor tissue.
Acceptable:
Specimen Type: Cytology
Container/Tube: Cytology slide (Direct smears or ThinPrep)
Slides: 1-2 slides (stained and coverslipped) with a minimum of 5,000 total nucleated cells
Collection Instructions: Submit 1-2 slides stained and coverslipped.
Additional Information: Cytology slides will not be returned.
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request Form (T729) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/oncology-request-form.pdf)
Useful For
Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
Identifying mutations that may help determine prognosis for patients with solid tumors
Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
Genetics Test Information
This extended RAS/RAF panel test uses targeted next-generation sequencing to evaluate for somatic mutations within the BRAF (exons 11 and 15), HRAS (exons 2 and 3), NRAS (exons 2, 3, 4), and KRAS (exons 2, 3, 4) genes. This includes, but is not limited to, the testing of somatic mutations in KRAS codons 12, 13, 59, 61, 117, 146; NRAS codons 12, 13, 59, 61,146; HRAS codons 12, 13, 61; and BRAF codons 594, 596, 600. See Targeted Gene Regions Interrogated by RAS/RAF Gene Panel in Special Instructions for details regarding the targeted gene regions identified by this test.
Of note, this test is performed to evaluate for somatic mutations within tumor samples. This test does not assess for germline alterations within the genes listed.
Highlights
This test provides evaluation of BRAF (including V600), HRAS, NRAS (includes codons 12, 13, 59, 61, and 146), and KRAS (includes codons 12, 13, 59, 61, 117, and 146) genes for somatic mutations.
Additional Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SLIRV | Slide Review in MG | No | Yes |
Testing Algorithm
When this test is ordered, slide review will always be performed at an additional charge.
Special Instructions
Method Name
Polymerase Chain Reaction (PCR)-Based Next Generation Sequencing
Reporting Name
RAS/RAF Panel, TumorSpecimen Type
VariesSpecimen Minimum Volume
Formalin-fixed, paraffin-embedded (FFPE) tissue block (preferred) or 1 slide stained with hematoxylin and eosin and 8 unstained, nonbaked slides
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Ambient (preferred) | |
| Frozen | ||
| Refrigerated | ||
Reference Values
An interpretive report will be provided.
Day(s) and Time(s) Performed
Monday through Friday; Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor
81210-BRAF (v-raf murine sarcoma viarl oncogene humolog B1) (eg, colon cancer), gene analysis, V600E variant
81275-KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) (eg, carcinoma) gene analysis, variants in codons 12 and 13
81403-HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2 sequence
81311-NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)
Slide Review
88381-Microdissection, manual
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| RASFP | RAS/RAF Panel, Tumor | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 36725 | Result Summary | 50397-9 |
| 36726 | Result | In Process |
| 36727 | Interpretation | 69047-9 |
| 36728 | Additional Information | 48767-8 |
| 36729 | Specimen | 31208-2 |
| 36730 | Source | 31208-2 |
| 36731 | Tissue ID | 81178-6 |
| 36732 | Released By | 18771-6 |